Community Building for Children’s Health: Lessons From Community Partnerships for Healthy Children

· This article describes Community Partnerships for Healthy Children (CPHC), a 10-year, $17 million initiative of the Sierra Health Foundation targeted at improving children’s health in northern California by mobilizing communities to use their assets. Implementation grants were modest ($50,000 annually), but technical assistance and communications support were also provided. · The initiative rolled out in four phases. Overall, a total of 31 communities participated in the initiative. Twenty-six communities remained through phase three, with 18 engaging in the final fourth phase. · Evidence indicates that CPHC improved the health of some children in some communities with regard to some outcomes, but did not improve the health of children at the population level. Community building appears to be well-suited to devising and implementing successful strategies to address straightforward health issues in the short term; more time, resources, and expertise are needed for more complex problems. · The community collaboratives achieved many of the intermediate goals of the initiative. The evidence is strong that communities did identify and respond to needs. · Most of the collaboratives on their own had access to few resources initially, but over time they were able to gather fiscal and human resources from a variety of sources and combine them to provide services such as recreation programs or family resource centers. Collaboratives involved in the final grant stage had been able to raise from other sources an amount nearly twice the foundation’s investment in CPHC. · The collaboratives were similar in role but differed in many other ways, such as the geographic scope and the existing assets. Collaboratives that had members with certain skills (such as grantwriting, public relations, and computer skills) had greater success

Reduced erbium-doped ceria nanoparticles: one nano-host applicable for simultaneous optical down- and up-conversions

This paper introduces a new synthesis procedure to form erbium-doped ceria nanoparticles (EDC NPs) that can act as an optical medium for both up-conversion and down-conversion in the same time. This synthesis process results qualitatively in a high concentration of Ce(3+) ions required to obtain high fluorescence efficiency in the down-conversion process. Simultaneously, the synthesized nanoparticles contain the molecular energy levels of erbium that are required for up-conversion. Therefore, the synthesized EDC NPs can emit visible light when excited with either UV or IR photons. This opens new opportunities for applications where emission of light via both up- and down-conversions from a single nanomaterial is desired such as solar cells and bio-imaging

Diseño y prototipado de un carrito de la compra capaz de seguir a una persona y evitar obstáculos

The aim of this Final Year Project was to design a shopping trolley that is able to navigate autonomously following a human within a 3 feet distance, transport a load up to 20 kg and avoid collisions. Due to the large weight of the load, it has been decided to build a smaller prototype and then choose the components needed to build the real size trolley. One infrared transmitter is attached to the body of the target person and several infrared phototransistors are placed on the robot to calculate the relative position robot-person and the distance between them. A collision avoidance algorithm has been implemented using ultrasonic sensors for detecting the nearest obstacles. An ARM mbed NXP LPC1768 microcontroller coordinates every sensor measure and control calculation. It also controls the power stage designed for driving the motors

Enhanced erbium-doped ceria nanostructure coating to improve solar cell performance

This paper discusses the effect of adding reduced erbium-doped ceria nanoparticles (REDC NPs) as a coating on silicon solar cells. Reduced ceria nanoparticles doped with erbium have the advantages of both improving conductivity and optical conversion of solar cells. Oxygen vacancies in ceria nanoparticles reduce Ce4+ to Ce3+ which follow the rule of improving conductivity of solar cells through the hopping mechanism. The existence of Ce3+ helps in the down-conversion from 430 nm excitation to 530 nm emission. The erbium dopant forms energy levels inside the low-phonon ceria host to up-convert the 780 nm excitations into green and red emissions. When coating reduced erbium-doped ceria nanoparticles on the back side of a solar cell, a promising improvement in the solar cell efficiency has been observed from 15% to 16.5% due to the mutual impact of improved electric conductivity and multi-optical conversions. Finally, the impact of the added coater on the electric field distribution inside the solar cell has been studied

STI-2062-1

This project investigated solar variability, power conversion and electric power grid response aspects of high penetration solar PV. These are the primary determining factors for acceptable penetration levels. Therefore, the study not only focused on the power system interactions, but also on the design of advanced power conditioners to explore more efficient design options and to look into advanced control impacts to the higher penetration PV deployment systems. Through extensive laboratory and field testing, the team gathered the essential information to better understand grid characteristics, PV systems configuration and power conditioning systems

Incidence of severe retinopathy of prematurity before and after a modest reduction in target oxygen saturation levels

Previous studies suggest that reducing target oxygen saturation levels to 85–93% decreases the incidence of severe retinopathy of prematurity (ROP). Our aim was to determine if a more modest reduction in target oxygen saturation levels also reduces ROP incidence

Phenotypic Characterization of EIF2AK4 Mutation Carriers in a Large Cohort of Patients Diagnosed Clinically With Pulmonary Arterial Hypertension.

BACKGROUND: Pulmonary arterial hypertension (PAH) is a rare disease with an emerging genetic basis. Heterozygous mutations in the gene encoding the bone morphogenetic protein receptor type 2 (BMPR2) are the commonest genetic cause of PAH, whereas biallelic mutations in the eukaryotic translation initiation factor 2 alpha kinase 4 gene (EIF2AK4) are described in pulmonary veno-occlusive disease/pulmonary capillary hemangiomatosis. Here, we determine the frequency of these mutations and define the genotype-phenotype characteristics in a large cohort of patients diagnosed clinically with PAH. METHODS: Whole-genome sequencing was performed on DNA from patients with idiopathic and heritable PAH and with pulmonary veno-occlusive disease/pulmonary capillary hemangiomatosis recruited to the National Institute of Health Research BioResource-Rare Diseases study. Heterozygous variants in BMPR2 and biallelic EIF2AK4 variants with a minor allele frequency of <1:10 000 in control data sets and predicted to be deleterious (by combined annotation-dependent depletion, PolyPhen-2, and sorting intolerant from tolerant predictions) were identified as potentially causal. Phenotype data from the time of diagnosis were also captured. RESULTS: Eight hundred sixty-four patients with idiopathic or heritable PAH and 16 with pulmonary veno-occlusive disease/pulmonary capillary hemangiomatosis were recruited. Mutations in BMPR2 were identified in 130 patients (14.8%). Biallelic mutations in EIF2AK4 were identified in 5 patients with a clinical diagnosis of pulmonary veno-occlusive disease/pulmonary capillary hemangiomatosis. Furthermore, 9 patients with a clinical diagnosis of PAH carried biallelic EIF2AK4 mutations. These patients had a reduced transfer coefficient for carbon monoxide (Kco; 33% [interquartile range, 30%-35%] predicted) and younger age at diagnosis (29 years; interquartile range, 23-38 years) and more interlobular septal thickening and mediastinal lymphadenopathy on computed tomography of the chest compared with patients with PAH without EIF2AK4 mutations. However, radiological assessment alone could not accurately identify biallelic EIF2AK4 mutation carriers. Patients with PAH with biallelic EIF2AK4 mutations had a shorter survival. CONCLUSIONS: Biallelic EIF2AK4 mutations are found in patients classified clinically as having idiopathic and heritable PAH. These patients cannot be identified reliably by computed tomography, but a low Kco and a young age at diagnosis suggests the underlying molecular diagnosis. Genetic testing can identify these misclassified patients, allowing appropriate management and early referral for lung transplantation

Phenotypic Characterization of <i>EIF2AK4</i> Mutation Carriers in a Large Cohort of Patients Diagnosed Clinically With Pulmonary Arterial Hypertension

Background: Pulmonary arterial hypertension (PAH) is a rare disease with an emerging genetic basis. Heterozygous mutations in the gene encoding the bone morphogenetic protein receptor type 2 ( BMPR2 ) are the commonest genetic cause of PAH, whereas biallelic mutations in the eukaryotic translation initiation factor 2 alpha kinase 4 gene ( EIF2AK4 ) are described in pulmonary veno-occlusive disease/pulmonary capillary hemangiomatosis. Here, we determine the frequency of these mutations and define the genotype-phenotype characteristics in a large cohort of patients diagnosed clinically with PAH. Methods: Whole-genome sequencing was performed on DNA from patients with idiopathic and heritable PAH and with pulmonary veno-occlusive disease/pulmonary capillary hemangiomatosis recruited to the National Institute of Health Research BioResource–Rare Diseases study. Heterozygous variants in BMPR2 and biallelic EIF2AK4 variants with a minor allele frequency of &lt;1:10 000 in control data sets and predicted to be deleterious (by combined annotation-dependent depletion, PolyPhen-2, and sorting intolerant from tolerant predictions) were identified as potentially causal. Phenotype data from the time of diagnosis were also captured. Results: Eight hundred sixty-four patients with idiopathic or heritable PAH and 16 with pulmonary veno-occlusive disease/pulmonary capillary hemangiomatosis were recruited. Mutations in BMPR2 were identified in 130 patients (14.8%). Biallelic mutations in EIF2AK4 were identified in 5 patients with a clinical diagnosis of pulmonary veno-occlusive disease/pulmonary capillary hemangiomatosis. Furthermore, 9 patients with a clinical diagnosis of PAH carried biallelic EIF2AK4 mutations. These patients had a reduced transfer coefficient for carbon monoxide (K co ; 33% [interquartile range, 30%–35%] predicted) and younger age at diagnosis (29 years; interquartile range, 23–38 years) and more interlobular septal thickening and mediastinal lymphadenopathy on computed tomography of the chest compared with patients with PAH without EIF2AK4 mutations. However, radiological assessment alone could not accurately identify biallelic EIF2AK4 mutation carriers. Patients with PAH with biallelic EIF2AK4 mutations had a shorter survival. Conclusions: Biallelic EIF2AK4 mutations are found in patients classified clinically as having idiopathic and heritable PAH. These patients cannot be identified reliably by computed tomography, but a low K co and a young age at diagnosis suggests the underlying molecular diagnosis. Genetic testing can identify these misclassified patients, allowing appropriate management and early referral for lung transplantation. </jats:sec